Firefly Bio
Firefly Bio is a South San Francisco biotech that developed the Firelink degrader antibody conjugate (DAC) platform, which pairs antibody targeting with selective protein degraders to deliver more precise cancer medicines to solid tumors, including KRAS-driven cancers. Incubated with Versant Ventures, it debuted from stealth in February 2024 with a $94 million Series A. Johnson & Johnson acquired the company for $1 billion in cash, completing the deal in July 2026.
Acquired
Firefly Bio has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2022
Employees
11–50
Total Funding
$94M
1 rounds
Latest Valuation
$0.56B
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
1 signalCompleted $1B cash acquisition by Johnson & Johnson of Firefly Bio's Firelink DAC oncology platform
Full liquidity exit; all equity converts to $1B cash, company no longer independently held
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $94M across 1 rounds
Last updated 10-09-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Feb 15, 2024 | Series A Press release | $94M | — | Versant Ventures, MPM BioImpact |
Prominent Investors
Leadership
Scott Hirsch
CEO
Dan Kaplan
CSO
Sean Smith
SVP, ADC Discovery & Innovation
Vinayak Vittal
VP, Head of Corporate Development
Megan Williams
VP, Strategy and Portfolio Management
John Flygare
Co-Founder
Carolyn Bertozzi
Co-Founder
Bernhard Geierstanger
Co-Founder
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.